Journal
NATURE REVIEWS CANCER
Volume 6, Issue 9, Pages 688-701Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc1958
Keywords
-
Categories
Ask authors/readers for more resources
The transfer of polymer - protein conjugates into routine clinical use, and the clinical development of polymer-anticancer-drug conjugates, both as single agents and as components of combination therapy, is establishing polymer therapeutics as one of the first classes of anticancer nanomedicines. There is growing optimism that ever more sophisticated polymer-based vectors will be a significant addition to the armoury currently used for cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available